Idelalisib: Worse Outcomes in the Clinical Setting vs Clinical Trials

Idelalisib is used as monotherapy to treat relapsed follicular lymphoma (FL) and in conjunction with rituximab for relapsed chronic lymphocytic leukemia (CLL). There is a dearth of data on real-world population outcomes of this therapy. Researchers set out to discover how treatment outcomes of idelalisib for relapsed follicular lymphoma and chronic lymphocytic leukemia in the clinical setting compare with outcomes in clinical trials and found that in the clinical setting, there were less favorab...
Continue reading

Ibrutinib Plus R-CHOP for Non-Germinal Center DLBCL With Wyndham Wilson, MD

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, has a 5-year survival rate of 63%. However, patients with non-germinal center B-cell-like (non-GCB) disease and high MYC and BCL2 expression face a poorer prognosis, with limited treatment options. In the phase 3 PHOENIX trial, Wyndham Wilson, MD, the Head of the Lymphoma Therapeutics Section at the National Cancer Institute, and colleagues investigated a combination of ibrutinib and rituximab, cyclophosphami...
Continue reading

Fedratinib for Improved Quality of Life in Myelofibrosis With Ruben Mesa, MD

Patients with myelofibrosis can experience debilitating symptoms that negatively impact their quality of life. In the phase 3 JAKARTA trial, a team of researchers led by Ruben Mesa, MD, the Director of MD Anderson Cancer Center at the University of Texas, San Antonio, found that fedratinib, an oral JAK2 inhibitor, decreased symptom severity and markedly improved quality of life in patients with intermediate- or high-risk primary or secondary myelofibrosis. Dr. Mesa presented the results of the t...
Continue reading

Moxetumomab Pasudotox-Tdfk for Hairy Cell Leukemia With Robert Kreitman, MD

Hairy cell leukemia (HCL) comprises only 2% of all leukemias and has limited treatment options. In a phase 3 trial, a team of researchers led by Robert Kreitman, MD, a medical oncologist at the National Cancer Institute, found that moxetumomab pasudotox-tdfk, a recombinant CD22-directed cytotoxin, achieved a high rate of durable response in patients with relapsed/refractory HCL. Dr. Kreitman presented the long-term follow-up results of the trial at the American Society of Hematology (ASH) Annual...
Continue reading

Adding Daratumumab to VMP for Transplant-Ineligible Myeloma: Maria Victoria Mateos, MD, PhD

Over half of patients with newly diagnosed multiple myeloma (NDMM) are ineligible for autologous stem cell transplantation. For these patients, a combination therapy consisting of the proteasome inhibitor bortezomib with melphalan and prednisone is one of the preferred treatments. Adding daratumumab to standard regimens for transplant-ineligible NDMM and relapsed/refractory multiple myeloma has had promising results. Now, data from the phase 3 ALCYONE trial show that adding daratumumab to bortez...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.